SCUNGILLIS FIVE STAR PICKS

[detailman]

ATTH - late news out yesAtlas Therapeutics Corporation (OTCBB:ATTH) (the "Company"), the distributor and marketer of the world's only clinically validated myostatin inhibitor, MYO-T12®, announced today the release of a new corporate video presentation by JB Bernstein, President and Chief Executive Officer of the Company. In the video, Mr. Bernstein discusses the Company's progress to date including its plan to create and distribute a full line of revolutionary nutritional supplements designed to maximize the results for people who wish to live "High-Performance Lifestyles."

Click here to view the video: http://www.atlastherapeutics.com

Mr. Bernstein noted that "The Company's strategy is based on sourcing the highest grade raw ingredients, utilizing state-of-the-art science in its manufacturing and packaging procedures to bring to market the most effective fitness supplements available. This approach in producing and promoting MYO-T12 in the fitness supplement category has been well received. Ads for MYO-T12 featuring pro hockey legend Wayne Gretzky have garnered industry and consumer attention. MYO-T12 is available for sale on the Company's website (www.MYOT12.com) as well as other retailers including Amazon.com and supplement retail leader BodyBuilding.com."

Recently retired hockey great Jeremy Roenick tweeted, "www.myot12.com. It's the best product I've ever used to improve strength and shed weight, all natural too. Your body will never be the same."

Mixed Martial Arts and Jiu Jitsu champion, Daniel Gracie, is an avid user of the product and is bringing MYO-T12 to Brazil, where all the students in his academies can benefit from its effects.

MYO-T12 is the world's first clinically validated, myostatin-inhibiting dietary supplement. Myostatin is a protein naturally produced in our bodies which inhibits muscle growth and also increases with age. MYO-T12 provides individuals with a healthy method for building and maintaining lean muscle, enabling them to reach their fitness goals by reducing the body's levels of myostatin to allow one's natural growth hormones to perform at maximum efficiency. The supplement has been clinically validated to reduce average serum myostatin levels in the body by up to 46 percent within 12-18 hours after just one serving.

Dr. Robert Hariri, a member of the Company's Board of Directors and CEO of Celgene Cellular Therapeutics commented, "Myostatin may be one of the most important regulatory molecules to target in our efforts to shift the balance between muscle loss and the creation and retention of healthy lean muscle mass. Muscle loss, as a consequence of aging, chronic illness or injury is a silent, yet treatable epidemic."

To learn more about MYO-T12, visit http://www.myot12.com/

The Atlas Therapeutics Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10042

Cautionary Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

CONTACT: ATLAS/MYO-T12(R) MEDIA CONTACT:
Lisa LaFon - [phone]
[e-mail]

terday -